Investors seeking direct access to management teams in the life sciences sector will have an opportunity on Thursday, September 17, 2026, as B2i Digital, Inc. and Virtual Investor Conferences present the Life Sciences Virtual Investor Forum. The online event, hosted by Virtual Investor Conferences, will feature live 30-minute presentations and audience Q&A sessions with seven companies spanning a range of therapeutic areas and technologies.
According to the announcement, the lineup includes Sona Nanotech Inc., which is developing a photothermal cancer therapy built on gold nanorods; Raphael Pharmaceutical, focused on cannabinoid-based formulations for rheumatoid arthritis, chronic lung inflammation, and autoimmune disease; Amplia Therapeutics Ltd., with a pipeline of Focal Adhesion Kinase inhibitors for cancer and fibrosis; Adaptin Bio, Inc., advancing precision drug delivery technologies aimed at target tissues including behind the blood-brain barrier; Acurx Pharmaceuticals, Inc., developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens; CytoDyn Inc., studying a humanized monoclonal antibody in solid-tumor oncology; and 4DMedical Ltd., which offers FDA-cleared four-dimensional respiratory imaging.
The forum is scheduled to begin at 11:00 AM ET with Sona Nanotech, followed by Raphael Pharmaceutical at 11:30 AM ET. After a midday break, presentations resume at 2:00 PM ET with Amplia Therapeutics, then Adaptin Bio at 2:30 PM ET, Acurx Pharmaceuticals at 3:00 PM ET, CytoDyn at 3:30 PM ET, and 4DMedical at 4:00 PM ET. The agenda is subject to change. Event details and presenting company profiles are available at https://b2idigital.com/sept-17-life-sciences-virtual-investor-forum.
David Shapiro, Chief Executive Officer of B2i Digital, Inc., highlighted the value of the format: "Reading company filings is a great cure for insomnia, but if you want to stay awake and hear it directly from management, these conferences are the best way to get a real feel for the company. My favorite part is the Q&A and hearing how they handle the impromptu questions that are really on your mind."
For investors, the forum offers a rare chance to hear directly from executives across a diverse set of life sciences niches, from novel cancer therapies and antibiotics to respiratory imaging and cannabinoid-based treatments. The live Q&A sessions allow participants to probe management on strategy, clinical progress, and market potential in real time. Replays will be available on the B2i Digital and OTC Markets YouTube channels, extending the reach of the presentations.
The event also underscores the growing role of virtual investor conferences in connecting public companies with a broad investor audience. Virtual Investor Conferences, an OTC Markets Group Inc. property, regularly features companies from exchanges worldwide, including NYSE, Nasdaq, TSX, TSXV, CSE, ASX, LSE, and OTC Markets. B2i Digital serves as the Official Marketing Partner, leveraging its media network of over 800 news, broadcast, and trade outlets with a combined monthly audience exceeding 330 million, plus more than 1.7 million followers and 70,000 opt-in email subscribers.
Investors can register for the forum at https://www.virtualinvestorconferences.com/wcc/eh/4814904/category/150412/september-17th-life-sciences-virtual-investor-forum?utm_source=b2i&utm_medium=marketing&utm_campaign=0917SeptLifeScienceVIC. Additional information on B2i Digital's Featured Conferences, Featured Companies, and Featured Experts is available at https://b2idigital.com.
The forum's focus on cutting-edge areas such as photothermal therapy, cannabinoid therapeutics, and precision drug delivery reflects broader trends in life sciences innovation. For industry leaders, the presentations may signal emerging competitive landscapes and partnership opportunities. The inclusion of a new class of antibiotics targeting priority pathogens is particularly noteworthy given the global urgency around antimicrobial resistance. As these companies advance their pipelines, the investor forum provides a platform for them to articulate their value propositions and for investors to assess potential risks and rewards.
With the life sciences sector continuing to attract significant investment, events like this serve as a barometer for investor sentiment and technological momentum. The live format and on-demand replays ensure that interested parties can engage regardless of location or schedule. For those tracking developments in oncology, fibrosis, drug delivery, antibiotics, cannabinoid therapeutics, and respiratory imaging, the September 17 forum offers a concentrated look at several companies poised to make an impact.
